Clinigen signs exclusive UK supply and distribution agreement with PAION

Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical Services and Products company, announces it has signed an exclusive partnership agreement with PAION for the supply and distribution of key products into the UK.

The first product within the agreement will be Byfavo® (remimazolam) which has been approved by the European Commission in the EU in March 2021 and by the Medicines & Healthcare products Regulatory Agency (MHRA) in the UK in June 2021. Byfavo® is the first product developed by PAION to be approved and launched in Europe. In addition, PAION has two further products, GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), in its portfolio that have also been launched recently outside the UK.

Under the terms of the agreement Clinigen will manage the supply and distribution of PAION’s licensed products in the UK.

Sam Herbert, Chief Operating Officer and Head of Products Division, Clinigen, said:

“We are pleased to be partnering with PAION for their first commercial launch in the UK and to be able to offer Byfavo® to healthcare providers across the UK through our lifecycle platform. We look forward to building a long and successful relationship with PAION that can help patients in the UK get access to the healthcare they need.”

Katja Lundell, UK General Manager, PAION, said:

“We are delighted to partner with Clinigen for the commercial launch of Byfavo, leveraging their strong regulatory, supply and distribution capabilities to ensure broad access of this important product in the UK. We look forward to working with them on this and our other products.”

Contact details

Clinigen Group plc
Sam Herbert, Group Chief Operating Officer & Head of Products Division
Rob Fox, VP Investor Relations and Corporate Development
+44 (0) 1283 495010
investors@clinigengroup.com

Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Hodgson
Tel: +44 (0) 20 3709 5700
Clinigen@consilium-comms.com

PAION
Katja Lundell, UK General Manager
Tel: +44 (0) 7464 544 995
k.lundell@paion.com

Notes to Editors

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products company focused on providing ethical access to medicines. Its’ mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,000 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit http://www.clinigen.com

About PAION

PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. Remimazolam is approved in the U.S., the EU/EEA/UK and China for procedural sedation and in Japan and South Korea for general anesthesia.

In addition to Byfavo® (remimazolam), PAION has two further products, GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), in its portfolio. GIAPREZA® is a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. XERAVA® is a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

PAION’s mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors and other stakeholders in healthcare.

About Byfavo®

This product is subject to additional monitoring which will allow quick identification of new safety information. A copy of the Summary of Product Characteristics can be accessed at https://www.medicines.org.uk/emc/product/12746/smpc#gref.